Brief: Definium Therapeutics Announces First Patient Dosed In Ascend
12/05/2026 12:00
May 12 (Reuters) - Definium Therapeutics Inc DFTX.O: DEFINIUM THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN ASCEND, THE SECOND PHASE 3 PIVOTAL STUDY OF DT120 ODT IN MAJOR DEPRESSIVE DISORDER DEFINIUM THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN ASCEND, THE SECOND PHASE 3 PIVOTAL STUDY OF DT120 ODT IN MAJOR DEPRESSIVE DISORDER DEFINIUM THERAPEUTICS INC: TOPLINE DATA FROM 12-WEEK DOUBLE-BLIND PERIOD IS ANTICIPATED IN 2027 Source text: ID:nBwc1fG44a Further company coverage: DFTX.O ((Reuters.Briefs@thomsonreuters.com;))